scholarly journals Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease

2021 ◽  
Author(s):  
Aline D. Seger ◽  
Ezequiel Farrher ◽  
Christopher E.J. Doppler ◽  
Ana Gogishvili ◽  
Wieland A. Worthoff ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response ◽  
Aminobutyric Acid ◽  
Dopaminergic Therapy

Dopaminergic therapy does not affect body weight in Parkinson's disease patients

2006 ◽  
Vol 33 (S 1) ◽  
Author(s):  
C.G. Bachmann ◽  
C. Werner ◽  
E. Brunner ◽  
C. Trenkwalder
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Body Weight ◽  
Dopaminergic Therapy ◽  
Affect Body Weight

scholarly journals Extradural Motor Cortex Stimulation in Parkinson’s Disease: Long-Term Clinical Outcome

2021 ◽  
Vol 11 (4) ◽  
pp. 416
Author(s):  
Carla Piano ◽  
Francesco Bove ◽  
Delia Mulas ◽  
Enrico Di Stasio ◽  
Alfonso Fasano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Cortex ◽  
Clinical Outcome ◽  
Motor Cortex Stimulation ◽  
Dopaminergic Therapy

Previous investigations have reported on the motor benefits and safety of chronic extradural motor cortex stimulation (EMCS) for patients with Parkinson’s disease (PD), but studies addressing the long-term clinical outcome are still lacking. In this study, nine consecutive PD patients who underwent EMCS were prospectively recruited, with a mean follow-up time of 5.1 ± 2.5 years. As compared to the preoperatory baseline, the Unified Parkinson’s Disease Rating Scale (UPDRS)-III in the off-medication condition significantly decreased by 13.8% at 12 months, 16.1% at 18 months, 18.4% at 24 months, 21% at 36 months, 15.6% at 60 months, and 8.6% at 72 months. The UPDRS-IV decreased by 30.8% at 12 months, 22.1% at 24 months, 25% at 60 months, and 36.5% at 72 months. Dopaminergic therapy showed a progressive reduction, significant at 60 months (11.8%). Quality of life improved by 18.0% at 12 months, and 22.4% at 60 months. No surgical complication, cognitive or behavioral change occurred. The only adverse event reported was an infection of the implantable pulse generator pocket. Even in the long-term follow-up, EMCS was shown to be a safe and effective treatment option in PD patients, resulting in improvements in motor symptoms and quality of life, and reductions in motor complications and dopaminergic therapy.

THE ROLE OF CIRCADIAN REGULATION OF GHRELIN LEVELS IN PARKINSON’S DISEASE (LITERATURE REVIEW)

2021 ◽  
Vol 74 (7) ◽  
pp. 1750-1753
Author(s):  
Kateryna A. Tarianyk ◽  
Nataliya V. Lytvynenko ◽  
Anastasiia D. Shkodina ◽  
Igor P. Kaidashev
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clock Genes ◽  
Biological Rhythms ◽  
Circadian Regulation ◽  
Diurnal Changes ◽  
Dopaminergic Therapy ◽  
Peripheral Oscillators ◽  
Genes Expression

The paper is aimed at the analysis of the role of the circadian regulation of ghrelin levels in patients with Parkinson’s disease. Based on the literature data, patients with Parkinson’s disease have clinical fluctuations in the symptoms of the disease, manifested by the diurnal changes in motor activity, autonomic functions, sleep-wake cycle, visual function, and the efficacy of dopaminergic therapy. Biological rhythms are controlled by central and peripheral oscillators which links with dopaminergic neurotransmission – core of the pathogenesis of Parkinson`s disease. Circadian system is altered in Parkinson`s disease due to that ghrelin fluctuations may be changed. Ghrelin is potential food-entrainable oscillator because it is linked with clock genes expression. In Parkinson`s disease this hormone may induce eating behavior changing and as a result metabolic disorder. The “hunger hormone” ghrelin can be a biomarker of the Parkinson’s disease, and the study of its role in the pathogenesis, as well as its dependence on the period of the day, intake of levodopa medications to improve the effectiveness of treatment is promising.

The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease

2009 ◽  
Vol 24 (5) ◽  
pp. 762-766 ◽  
Author(s):  
Julia Vaamonde ◽  
José M. Flores ◽  
Roberto Weisser ◽  
Ramón Ibañez ◽  
José A. Obeso
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response

THUR 117 The L-DOPA response in pathologically confirmed parkinson’s disease

2018 ◽  
Vol 89 (10) ◽  
pp. A12.4-A13
Author(s):  
Vanessa Pitz ◽  
Naveed Malek ◽  
Katherine A Grosset ◽  
Donald G Grosset
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response ◽  
Standard Treatment ◽  
Disease Onset ◽  
Lewy Body Disease ◽  
Amyloid Angiopathy ◽  
Brain Pathology ◽  
Diffuse Lewy Body Disease ◽  
Available Information

Backgroundl-dopa is the standard treatment for Parkinson’s disease, but the response is variable.AimSystematic review of papers reporting the l-dopa response (motor response and/or complications) in pathologically confirmed Parkinson’s disease.Results467 cases of pathologically confirmed Parkinson’s were identified: 60.2% male, age at disease onset 63.3 years (SD 10.3), age at death 76.7 years (SD 7.8). Data on a graded l-dopa response were available in 411 cases (88.0% of 467). The motor response was excellent in 148/411 cases (36.0%), good in 179/411 (43.6%), moderate in 51/411 (12.4%) and poor/absent in 33/411 (8.0%). Data about motor complications were available for 161 patients: 71/161 (44.1%) had motor fluctuations and 89/161 (55.3%) had dyskinesia. Comorbid brain pathology was evaluated in 251/411 cases (61.1%), and was present in 148/251 (59.0%): cerebrovascular in 65/148 (43.9%), Alzheimer’s in 55/148 (37.2%), amyloid angiopathy in 18/148 (12.2%), and diffuse Lewy body disease in 10/148 (6.8%). Data linking the graded l-dopa response to comorbid pathologies were available in only 17 cases, of whom 8/17 (47.1%) had a good/excellent response.ConclusionThere is variation in the l-dopa response in pathologically confirmed Parkinson’s disease. The limited available information suggests a possible association of motor response to comorbid brain pathology.

scholarly journals Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies

2021 ◽  
Vol 12 ◽  
Author(s):  
Jun-Fang Zhang ◽  
Xi-Xi Wang ◽  
Ya Feng ◽  
Robert Fekete ◽  
Joseph Jankovic ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Broad Spectrum ◽  
Impulse Control ◽  
Compulsive Buying ◽  
Therapeutic Strategies ◽  
Impulse Control Disorders ◽  
Dopaminergic Therapy ◽  
Disease Epidemiology ◽  
Tremendous Impact

Impulse control disorders (ICDs) in Parkinson's disease (PD) are aberrant behavior such as pathological gambling, hypersexuality, binge eating, and compulsive buying, which typically occur as a result of dopaminergic therapy. Numerous studies have focused on the broad spectrum of ICDs-related behaviors and their tremendous impact on patients and their family members. Recent advances have improved our understanding of ICDs. In this review, we discuss the epidemiology, pathogenesis and treatment of ICDs in the setting of PD.

Sign in / Sign up

Export Citation Format

Share Document